Hello, everyone, and how are you today? We are doing just fine, thank you. After all, clear blue skies and crisp temperatures are enveloping the Pharmalot campus, where the official mascot is hounding us to play and Mrs. Pharmalot, our culinary queen, is working on a new creation in the cafeteria. As for us, we are busy as usual sipping cups of stimulation — our choice today is, once again, butter pecan — and rummaging through our to-do list. We are especially busy, in fact, as we plan for a STAT soiree later (details here). Feel free to join us. Meanwhile, here are a few tidbits to help you get cracking. Hope all goes well today and that you stay safe. …
Some of the biggest names in biotech venture capital have charged their startups millions of dollars in ‘consulting fees’ over the past decade, effectively taking back a small portion of the money they invested in a company, STAT reports. The fees are usually charged in exchange for certain additional services, such as when a venture capital firm loans an experienced executive to a startup to lead the company through its early days. They are far more common for venture capital firms that fund life science companies than for those focusing on technology or other sectors. Most of biotech venture capital’s biggest names have charged fees to portfolio companies directly or through an intermediary. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2021/12/09/pharmalittle-biotech-vc-firms-covid19-pandemic-fda-astrazeneca/
